Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.

Autor: do Nascimento TA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Nogami PY; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., de Oliveira CF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Neto WFF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., da Silva CP; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Ribeiro ACS; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., de Sousa AW; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Freitas MNO; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Chiang JO; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Silva FA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., das Chagas LL; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Carvalho VL; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Azevedo RSS; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Vasconcelos PFC; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Department of Biological and Health Sciences, University of Pará State, Belém 66087-670, Pará, Brazil., Costa IB; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Costa IB; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Barbagelata LS; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., das Chagas Junior WD; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., da Penha Junior ET; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Soares LS; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Viana GMR; Malaria Basic Research Laboratory, Parasitology Section, Evandro Chagas Institute, Health Surveillance Secretariat, Brazilian Ministry of Health, Ananindeua 67000-000, Pará, Brazil., Amarilla AA; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Modhiran N; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Watterson D; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.; The Australian Institute for Biotechnology and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia.; Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, QLD 4072, Australia., Casseb LMN; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Martins LC; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil., Henriques DF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.; Graduate Program in Virology, Evandro Chagas Institute, Ananindeua 67030-000, Pará, Brazil.
Jazyk: angličtina
Zdroj: Vaccines [Vaccines (Basel)] 2024 Jul 18; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 18.
DOI: 10.3390/vaccines12070792
Abstrakt: Several technological approaches have been used to develop vaccines against COVID-19, including those based on inactivated viruses, viral vectors, and mRNA. This study aimed to monitor the maintenance of anti-SARS-CoV-2 antibodies in individuals from Brazil according to the primary vaccination regimen, as follows: BNT162b2 (group 1; 22) and ChAdOx1 (group 2; 18). Everyone received BNT162b2 in the first booster while in the second booster CoronaVac, Ad26.COV2.S, or BNT162b2. Blood samples were collected from 2021 to 2023 to analyze specific RBD (ELISA) and neutralizing antibodies (PRNT50). We observed a progressive increase in anti-RBD and neutralizing antibodies in each subsequent dose, remaining at high titers until the end of follow-up. Group 1 had higher anti-RBD antibody titers than group 2 after beginning the primary regimen, with significant differences after the 2nd and 3rd doses. Group 2 showed a more expressive increase after the first booster with BNT162B2 (heterologous booster). Group 2 also presented high levels of neutralizing antibodies against the Gamma and Delta variants until five months after the second booster. In conclusion, the circulating levels of anti-RBD and neutralizing antibodies against the two variants of SARS-CoV-2 were durable even five months after the 4th dose, suggesting that periodic booster vaccinations (homologous or heterologous) induced long-lasting immunity.
Databáze: MEDLINE
Externí odkaz: